Why Axsome Therapeutics Stock Rocketed Higher This Week
Shares of the developmental-stage biotech Axsome Therapeutics (NASDAQ: AXSM) vaulted higher by a healthy 25% through Thursday's close this week, according to data from S&P Global Market Intelligence. The U.S. Food and Drug Administration (FDA) still hasn't issued a regulatory decision for the company's major depressive disorder drug candidate known as AXS-05. Axsome posted several job openings on its website and other social media sites, indicating a need for individuals to work on AXS-05's commercial launch.
